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Background: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) with 
active disease, but normal levels of acute phase protein C-reactive protein (CRP) was identified 
using ultrasound (US) to assess joint erosions and disease activity (significant Power Doppler) . 
We questioned whether these patients had delayed diagnosis or were undertreated. 
Understanding the underlying immune pathology in this subgroup could aid therapeutic targeting 
in patients whose needs are currently unmet.  
Methods: 44 RA patients with active synovitis (≥1 joint with PD) were recruited, 29 nCRP 
(≤5mg/L) and 15 hCRP (>5mg/L). Peripheral blood mononuclear cells (PBMCs), serum and 
clinical data were collected.  Blood was also collected from 18 age and sex matched healthy 
controls (HC). PBMC immunophenotyping was performed using flow cytometry. Serum cytokines 
were assessed using Cytometric Bead Array. Plasma was subjected to SOMAscan™ Proteomic 
Assay. Serum amyloid A (SAA) and serum IL-6/IL-6Rα complex were measured using ELISA. 
 
Results: Patients with nCRP had an increased erosion accrual rate compared to hCRP patients 
(p=0.022) reflecting more disease-associated joint damage; other clinical and laboratory 
parameters were not significantly different including expression of acute phase reactant serum 
amyloid A which was increased in both patient groups compared to HCs (p=<0.05). Serum 
cytokines IL-6, IL-1β, IL-10, IL-12/IL-23, IL-17A, IL-17F and IL-21  and serum soluble IL-6/IL-6Rα 
complex were elevated in both patient groups compared to HC (p=<0.001). Furthermore, 
significant positive correlations existed between serum cytokine levels in the hCRP patients, but 
these were lost in nCRP patients. In particular, the positive correlation between IL-6 and IL-1β in 
hCRP patients (p=<0.001, r=0.5047) was absent in nCRP patients. Since IL-6 and IL-1β trigger 
CRP production the results suggested a defect in cytokine (potentially IL-6) signaling or an IL-6-
independent disease mechanism. 
nCRP patients had an anti-inflammatory immune cell phenotype with significantly increased 
Foxp3+CD161+Tregs (p=0.014) which have been negatively correlated with CRP levels and 
increased Treg-suppressive capacity. Alternatively, hCRP patients had an activated T-cell 
phenotype including increased central memory T-cells (p=0.024). However, no significant 
differences in ex vivo CD4+ T cell cytokine production were identified between the two patient 
groups matching the serum cytokine profiles. Strikingly proteomic analysis identified significant 
increases in complement components (C3b and C5) and SAP in hCRP compared to nCRP 
patients indicating decreased complement activation in the nCRP patients. 
 
Conclusion: This study stratifies distinct patient subgroups using detailed immunophenotyping 
and proteomic signatures which could translate to improved patient-specific therapies. 
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